 Vericel Corporations NASDAQ:VCEL development partner, MediWound Ltd NASDAQ:MDWD, received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal in adults with deep partial-thickness or full-thickness burns. The FDA identified issues related to the Chemistry, Manufacturing, and Controls CMC section of the application and requested that MediWound provide additional CMC information. 